The data show favorable survival and patient outcomes with Impala support from the best practices in HRPCI, in contrast to the results of the CHIP-BCIS3 study. Company announcement - FT.com.
The data show favorable survival and patient outcomes with Impala support from the best practices in HRPCI, in contrast to the results of the CHIP-BCIS3 study. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in